EVERSANA, a leading provider of global commercial services to the life sciences industry, has announced two strategic ...

Describing the current treatment landscape for primary and secondary bone cancer, Romness explains the potential of their own ...

US Senators Bernie Sanders and Angus King have introduced a bill that seeks to ban direct-to-consumer (DTC) advertising by ...

The announcement builds on AZ's announcement earlier this year that it will invest $2.5 billion in an R&D facility in China, ...

Alpha-1 is a microcosm of the rare disease world. The challenges we face, late diagnoses, inconsistent care, and unaffordable ...

A fourth revolution in cancer care is taking shape, one that steps away from the current well-trodden path. This revolution ...

The Health and Human Services (HHS) Secretary named eight hand-picked members of the Advisory Committee on Immunisation ...

England is the first country in the world to make GSK's anti-BCMA drug Blenrep available to patients with the haematological ...

Full results from the first phase 3 trial of UCB and Biogen's anti-CD40L antibody dapirolizumab pegol (DZP) in systemic lupus ...

The first biosimilars of AstraZeneca/Alexion's blockbuster complement C5 inhibitor Soliris have been launched in the US at a discount to the brand. Both Amgen's Bkemv and Teva/Samsung Bioepis ...

GSK decided to abandon a TIGIT-targeted drug for cancer this week, then immediately hatched a plan to replace it with a late-stage candidate for metabolic dysfunction-associated steatohepatitis ...

The Biden administration has made various organisational and financial efforts to kick-start a renewed push against cancer. Ben Hargreaves looks at how the Moonshot initiative has been restarted ...